Successful management of an arteriovenous malformation with trametinib in a patient with capillary‐malformation arteriovenous malformation syndrome and cardiac compromise. Issue 2 (10th January 2022)

• Record Type: Journal Article
• Authors: Nicholson, Cynthia L.; Flanagan, Siobhan; Murati, Michael; Boull, Christina; McGough, Erin; Ameduri, Rebecca; Weigel, Brenda; Maguiness, Sheilagh
• Is Part Of: Pediatric dermatology. Volume 39:Issue 2(2022)
• Page Start: 316
• Page End: 319
• Publication Date: 2022-01-10
• Subjects: MEK inhibitor -- skin signs of systemic disease -- therapy‐systemic -- trametinib -- vascular malformation; Pediatric dermatology -- Periodicals; Children -- Diseases -- Periodicals; 618.925
• DOI: 10.1111/pde.14912
• Languages: English
• ISSNs: 0736-8046

Abstract

Abstract: Capillary malformation‐arteriovenous malformation (CM‐AVM) syndrome is an autosomal dominant condition characterized by multifocal, noncontiguous pink patches on the skin that often have a surrounding pale halo. In some cases, an association with a fast flow, arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16‐year‐old woman with CM‐AVM syndrome and significant cardiac compromise successfully treated with trametinib, a mitogen‐activated protein kinase (MEK) inhibitor.